Summary: Rolling Stone reports on the results of the historic psychedelic study conducted by researchers from the Centre for Psychedelic Research at Imperial College London. Published in the New England Journal of Medicine, the study “indicated that psilocybin could potentially be a more efficient, and equally effective, treatment for depression as a common antidepressant,” according to Rolling Stone.
In the article, MAPS Public Benefit Corporation (MAPS PBC) Chief Medical Officer Corine de Boer, M.D., Ph.D., highlights that no safety concerns arose among the psilocybin group, which may support public education efforts surrounding psychedelics. “The durability of these results need to be confirmed in a larger with a longer follow-up but these results are very promising for the field of psychedelic medicine.”
Originally appearing here.